AOC Splashes Thousands In Campaign Funds On Psychiatrist Specializing In Ketamine Therapy

Rep. Alexandria Ocasio-Cortez’s (D- NY) campaign splashed close to $19,000 in campaign funds last year to a Boston-area psychiatrist affiliated with a chain of clinics that specialize in ketamine-based treatments for mental-health conditions, according to the New York Post.

Disclosures filed with the Federal Election Commission indicate that Ocasio-Cortez’s campaign committee made three payments totaling $18,725 in 2025 to Dr. Brian Boyle, chief psychiatric officer at Stella Mental Health. The expenditures were recorded as “leadership training and consulting”: $11,550 in March, $2,800 in May and $4,375 in October.

Dr. Boyle, a Harvard Medical School graduate who previously served as an attending psychiatrist at McLean Hospital and Massachusetts General Hospital, focuses on interventional psychiatry. Stella Mental Health offers treatments including intravenous ketamine infusions, Spravato nasal spray, transcranial magnetic stimulation and other approaches aimed at conditions such as treatment-resistant depression, post-traumatic stress disorder and anxiety. The clinics market these services to patients who have not responded to conventional therapies, and ketamine-based options have gained attention in recent years among certain professional and celebrity circles seeking alternative mental-health interventions, the Post reports.

It’s unclear whether the money was actually spent on ketamine therapy as the expenses were mysteriously labeled as “leadership training and consulting,” the Post said.

Ketamine, originally developed as an anesthetic, has shown promise in providing rapid symptom relief for some patients with severe, treatment-resistant depression, according to clinical studies. The only FDA-approved ketamine-derived medication for psychiatric use is esketamine nasal spray, Spravato, first cleared in 2019 as an adjunct to oral antidepressants for treatment-resistant depression. In early 2025, the agency expanded approval to allow its use as a monotherapy for adults who have not responded adequately to at least two prior oral antidepressants.

Administration of Spravato remains tightly regulated under a Risk Evaluation and Mitigation Strategy program, requiring supervised use in certified healthcare settings, post-dose monitoring for at least two hours due to potential side effects such as dissociation, sedation and elevated blood pressure, and restrictions on driving.

Off-label intravenous ketamine infusions, such as those offered by clinics like Stella, lack the same level of FDA approval and long-term safety data. While some patients report substantial short-term benefits, medical experts and regulators have raised concerns about overhype, variable evidence for sustained efficacy, risks of dependency in vulnerable populations, and potential for misuse. Critics, including specialists at institutions such as Yale and the Cleveland Clinic, have pointed to limited longitudinal studies and questions about whether the treatments deliver lasting reductions in suicide risk or serve primarily as a temporary bridge.